PLoS Negl Trop Dis 11(2): e0005356 -Published: February 23, 2017 21 pp
Key populations brief
Accessed November 2017
Human Rights, Minimum Standards and Monitoring at the European and International Levels
Материалы научно-практической конференции с международным участием «Достижения в нейробиологии и терапии болезни Альцгеймера», посвященной памяти профессора Э..... Штернберга (Москва, 6 декабря 2013 г.)
more
Endorsed by the CCM Georgia on April 15th 2015
Accessed: 26.09.2019
Malaria deaths, Malaria cases
Steady progress in the scaleup of VMMC as an HIV prevention intervention in 15 eastern and southern African countries before the SARS-CoV2 pandemic
Accessed on 10.04.2023
While virtually unheard of in developed countries, NTDs are a group of medically diverse parasitic and bacterial infectious diseases common in tropical and subtropical areas. NTDs affect more than 1.5 billion people annually, causing death, blindness, disfigurement, chroni...c pain, cognitive impairment and other long-term disabilities that create obstacles to education, employment, economic growth and overall
development. When measured in disability-adjusted life years (DALYs), the NTD burden is greater than malaria or tuberculosis.
more
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more